Sugi Predict

Sugi Predict / Compounds / SCHEMBL320908

SCHEMBL320908

SCHEMBL320908

Oc1ccc(C(F)(F)F)cc1-c1ccnnc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.46
▸ KIF11 P52732 1/20 0.40
▸ SCN9A Q15858 11/20 0.40
▸ FPR2 P25090 1/20 0.40
▸ ALOX5AP P20292 2/20 0.40
▸ FEN1 P39748 2/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TOP2A P11388 1/20 0.39
▸ PIK3CA P42336 1/20 0.38
▸ CYP2C9 P11712 2/20 0.37
▸ SCN5A Q14524 1/20 0.37
▸ SCN1A P35498 1/20 0.37
▸ SCN2A Q99250 1/20 0.37
▸ SCN8A Q9UQD0 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ MAP2K4 P45985 1/20 0.37
▸ MAPKAPK2 P49137 1/20 0.37
▸ MAPKAPK3 Q16644 1/20 0.37
▸ MAPK6 Q16659 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321794 0.89 S1PR1 (0.49) S1PR1KIF11ALOX5APFEN1PIK3CA
SCHEMBL29131926 0.88 ALOX5AP (0.50) S1PR1KIF11SCN9AFPR2ALOX5AP
SCHEMBL322243 0.85 EPHX2 (0.44) S1PR1KIF11SCN2AALDH1A1
SCHEMBL5990646 0.83 KIF11 (0.57) S1PR1KIF11SCN9AMEN1KMT2A
SCHEMBL20403726 0.82 S1PR1 (0.44) S1PR1KIF11SCN9AFPR2ALOX5AP
SCHEMBL17248009 0.82 S1PR1 (0.44) S1PR1KIF11SCN9AFPR2CYP2C9
SCHEMBL320085 0.82 SCN9A (0.44) S1PR1KIF11SCN9AFPR2CYP2C9
SCHEMBL29242955 0.81 S1PR1 (0.40) S1PR1KIF11SCN9AFPR2ALOX5AP
SCHEMBL319681 0.80 S1PR1 (0.43) S1PR1KIF11SCN9AFPR2CYP2C9
SCHEMBL5990332 0.79 CYP11B1 (0.51) S1PR1KIF11SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106397426-A 1,3,4-thiadiazole compound and preparation method thereof 广东环境保护工程职业学院 2017-02-15 — — CN claimed
CN-106397425-A 1,3,4-thiadiazole compound and preparation method thereof 广东环境保护工程职业学院 2017-02-15 — — CN claimed
EP-3293184-B1 PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA LP (US) 2020-12-16 — — EP disclosed
EP-3293184-B1 PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA LP (US) 2020-12-16 — — EP disclosed
US-10774050-B2 Pyrimidines as sodium channel blockers PURDUE PHARMA, L.P. (US) 2020-09-15 — — US disclosed
US-10196364-B2 Pyrimidine carboxamides as sodium channel blockers PURDUE PHARMA L.P. (US) 2019-02-05 — — US disclosed
US-10196364-B2 Pyrimidine carboxamides as sodium channel blockers PURDUE PHARMA L.P. (US) 2019-02-05 — — US disclosed
US-20190002412-A1 PYRIMIDINES AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA L.P. 2019-01-03 — — US disclosed
US-10059675-B2 Pyrimidines as sodium channel blockers PURDUE PHARMA L.P. (US) 2018-08-28 — — US disclosed
EP-2964639-B1 PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA LP (US) 2018-05-02 — — EP disclosed
EP-2964639-B1 PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA LP (US) 2018-05-02 — — EP disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 — — US disclosed
EP-2385938-A1 SULFONAMIDE DERIVATIVES Pfizer Limited (GB) 2011-11-16 — — EP disclosed
US-8040476-B2 Display device and method of producing the same MITSUBISHI ELECTRIC CORPORATION (JP) 2011-10-18 — — US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 — — US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 — — US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 — — US disclosed
WO-2010079443-A1 SULFONAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-07-15 — — WO disclosed
WO-2010079443-A1 SULFONAMIDE DERIVATIVES PFIZER LIMITED (GB) 2010-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196364-B2 Pyrimidine carboxamides as sodium channel blockers CACNA1A, TRPV1, TRPA1 S1PR1 520/4885KIF11 4151/4885SCN9A 85/4885
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 S1PR1 2746/4885KIF11 2498/4885SCN9A 73/4885
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A S1PR1 710/4885KIF11 3860/4885SCN9A 13/4885
US-10059675-B2 Pyrimidines as sodium channel blockers P2RX3, CACNA1A, P2RX4 S1PR1 304/4885KIF11 3872/4885SCN9A 83/4885
US-20190002412-A1 PYRIMIDINES AS SODIUM CHANNEL BLOCKERS P2RX3, CACNA1A, P2RX4 S1PR1 304/4885KIF11 3872/4885SCN9A 83/4885
US-10774050-B2 Pyrimidines as sodium channel blockers P2RX3, CACNA1A, P2RX4 S1PR1 304/4885KIF11 3872/4885SCN9A 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.